Roche's Risdiplam Data Stir Up SMA Market
Executive Summary
Positive results for the Swiss major's oral therapy suggests that Biogen and Ionis' monopoly of the lucrative spinal muscular atrophy market with Spinraza could soon be under considerable threat.
You may also be interested in...
Roche Makes Case For Its Oral SMA Drug Risdiplam As Filings Beckon
Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.
Biogen To Launch Phase III Alzheimer’s Prevention Study
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.
Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire
Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.